KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Research & Development (2016 - 2025)

Travere Therapeutics' Research & Development history spans 13 years, with the latest figure at $57.9 million for Q4 2025.

  • For Q4 2025, Research & Development fell 6.76% year-over-year to $57.9 million; the TTM value through Dec 2025 reached $206.0 million, down 5.28%, while the annual FY2025 figure was $206.0 million, 5.28% down from the prior year.
  • Research & Development reached $57.9 million in Q4 2025 per TVTX's latest filing, up from $51.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $66.5 million in Q2 2023 to a low of $46.9 million in Q1 2025.
  • Average Research & Development over 5 years is $55.1 million, with a median of $55.5 million recorded in 2022.
  • Peak YoY movement for Research & Development: skyrocketed 68.26% in 2021, then fell 18.29% in 2024.
  • A 5-year view of Research & Development shows it stood at $53.0 million in 2021, then increased by 9.6% to $58.1 million in 2022, then increased by 2.86% to $59.7 million in 2023, then rose by 3.88% to $62.1 million in 2024, then fell by 6.76% to $57.9 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Research & Development are $57.9 million (Q4 2025), $51.9 million (Q3 2025), and $49.4 million (Q2 2025).